Frankfurt - Delayed Quote EUR

Ipsen S.A. (I7G.F)

101.90

-1.90

(-1.83%)

As of 8:20:01 AM GMT+2. Market Open.

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 April 2025 83,814,526 Gross total* of voting rights: 131,926,335 Net total*

GlobeNewswire yesterday

IPSEF

IPSEY
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO dual PPARα/δ activation impacts inflammation and fibrosisPPARα activation linked to fatigue improvement in primary biliary cholangitis PARIS, FRANCE, 7 May 2025 Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced new data from two late-breaking presentations on IQIRVO® (elafibranor) during the Europea

GlobeNewswire 7 days ago

IPSEF

IPSEY
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura’s involvement in major transfo

GlobeNewswire 8 days ago

IPSEF

IPSEY
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

Information relating to the holding of the Combined Shareholders’ Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANCE, 30 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 21 May 2025 at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des A

GlobeNewswire 13 days ago

IPSEF

IPSEY
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment optionsPatients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase (ALP)Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placeboA significant improvement in pruritus was

GlobeNewswire 20 days ago

IPSEF

IPSEY
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025. Q1 2025 % change % change €m Actual CER1 Oncol

GlobeNewswire 28 days ago

IPSEF

IPSEY
Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 March 2025 83,814,526 Gross total* of voting rights: 131,926,652 Net total*

GlobeNewswire 29 days ago

IPSEF

IPSEY
Ipsen publishes its 2024 Universal Registration Document

Ipsen publishes its 2024 Universal Registration Document PARIS, FRANCE, 8 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the filing of its 2024 Universal Registration Document with the French Autorité des Marchés Financiers (AMF) on 7 April 2025 and registered under the number D.25-0232. The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 70 rue Balard, 75015 Paris, France. The Universal Registration Document includes

GlobeNewswire last month

IPSEF

IPSEY
Ipsen announces issuance of €500 million inaugural Rated Public Bond

Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well r

GlobeNewswire last month

IPSEF

IPSEY
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

PARIS, FRANCE, March 12th, 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership Team (ELT) and report directly to Chief Executive Officer David Loew. In this newly created role, she will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indication

GlobeNewswire 2 months ago

IPSEF

IPSEY
Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 28 February 2025 83,814,526 Gross total* of voting rights: 131,933,057 Net tot

GlobeNewswire 2 months ago

IPSEF

IPSEY
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Ipsen SA (IPSEF) reports robust financial performance with a 9.9% sales increase and strategic pipeline developments, despite facing competitive pressures.

GuruFocus.com 2 months ago

IPSEY
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% in Neuroscience, and 7.3% in Oncology; Somatuline® (lanreotide) sales grew by 5.6%, while all other products, excluding Somatuline, achieved double-digit sales growth at 12.2%FY 2024 core operating income of €1,109m, growing 10.8% as reported, with core operating margin of 32.6% of total sales Conti

GlobeNewswire 2 months ago

IPSEF

IPSEY
Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 January 2025 83,814,526 Gross total* of voting rights: 131,933,045 Net tota

GlobeNewswire 3 months ago

IPSEF

IPSEY
Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 December 2024 83,814,526 Gross total* of voting rights: 131,939,858 Net tot

GlobeNewswire 4 months ago

IPSEF

IPSEY
Ipsen - Half year statement - 2024 12 31

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account: 24,701 shares€2,635,980.25 It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account: 12,751 shares€3,137,934.80 Between July

GlobeNewswire 4 months ago

IPSEF

IPSEY
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 November 2024 83,814,526 Gross total* of voting rights: 132,129,451 Net tot

GlobeNewswire 5 months ago

IPSEF

IPSEY
Ipsen and Biomunex enter agreement for cancer therapy

Biomunex could receive up to $610m, including upfront and milestone payments.

Pharmaceutical Technology 5 months ago

IPSEY
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Ipsen secures exclusive global rights to develop, manufacture and commercialize BMX-502, a pre-clinical novel T cell engager (TCE) with first-in-class potentialBMX-502 is a bispecific antibody engaging MAIT cells, a subset of non-conventional T cells, and targeting the clinically validated tumor antigen GPC3 to kill cancer cells PARIS, FRANCE; 03 December 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX

GlobeNewswire 5 months ago

IPSEF

IPSEY
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial Intrahepatic Cholestasis (PF

GlobeNewswire 5 months ago

IPSEF

IPSEY

Performance Overview

Return	I7G.F	CAC 40 (^FCHI)
YTD	-7.36%	+6.31%
1-Year	-12.98%	-4.61%
3-Year	+12.75%	+23.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ipsen S.A. (I7G.F)

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen publishes its 2024 Universal Registration Document

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen - Half year statement - 2024 12 31

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen and Biomunex enter agreement for cancer therapy

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Performance Overview